The Competition Commission of Pakistan (CCP) has imposed a penalty of Rs150 million on Reckitt Benckiser Pakistan Limited (respondent) for violation of Section 10 of the Competition Act 2010 in advertising/marketing claims about its product ‘Strepsils’, which have been found capable of misleading and deceiving under the Act. Square Distribution and Marketing System (Pvt) Limited filed a formal complaint, alleging that the company had been disseminating misleading information to consumers by creating impression of its product ‘Strepsils’ as a drug for sore throat and cough. It was alleged that the tablet was de-registered as a drug when acquired by the firm from Boots in 2005, and then re-launched with the disclaimer, “Non-medicated Lozenges.” However, the company made no effort to educate and inform the consumers regarding the discontinuation of medicinal ingredient in it.
Published in The Express Tribune, February 12th, 2021.
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ